Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Public ClinicalTrials.gov record NCT03007407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being done to look at the safety and response to the combination of two investigational drugs, tremelimumab and durvalumab, when given after radiation therapy for patients with microsatellite stable (MSS) metastatic colorectal cancer. Tremelimumab and durvalumab recognize specific proteins on the surface of cancer cells and trigger the immune system to destroy the cancer cells. In order to learn more about certain characteristics of colorectal cancer tumors, this study includes special research tests using samples from diagnostic tumors, fresh tumor samples from an area where the cancer has spread, and blood samples.
Study identification
- NCT ID
- NCT03007407
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2017 (Actual)
- Primary completion
- Apr 18, 2019 (Actual)
- Completion
- Aug 9, 2019 (Actual)
- Last update posted
- Dec 5, 2022
2017 – 2019
United States locations
- U.S. sites
- 18
- U.S. states
- 6
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| Smilow Cancer Hospital at Yale-New Haven | New Haven | Connecticut | 06510 | — |
| Smilow Cancer Hospital Care Center at North Haven | North Haven | Connecticut | 06473 | — |
| UF Health Davis Cancer Pavilion and Shands Med Plaza | Gainesville | Florida | 32608 | — |
| UF Health Shands Cancer Hospital | Gainesville | Florida | 32608 | — |
| UF Health Shands Hospital | Gainesville | Florida | 32610 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| University of Florida Health Cancer Center at Orlando Health | Orlando | Florida | 32806 | — |
| Centralia Oncology Clinic | Centralia | Illinois | 62801 | — |
| Cancer Care Specialists of Central Illinois | Decatur | Illinois | 62526 | — |
| Cancer Care Specialists of Central Illinois/Crossroads Cancer Center | Effingham | Illinois | 62401 | — |
| Cancer Care Specialists of Central Illinois-Swansea | Swansea | Illinois | 62226 | — |
| Trinity Health Michigan | Ann Arbor | Michigan | 48106 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| St. Joseph Mercy-Brighton | Brighton | Michigan | 48114 | — |
| St. Joseph Mercy-Canton | Canton | Michigan | 48188 | — |
| St Joseph Mercy-Chelsea | Chelsea | Michigan | 48118 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03007407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2022 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03007407 live on ClinicalTrials.gov.